Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors

Adaptimmune Therapeutics has received FDA approval for Tecelra (originally afamitresgene autoleucel), the first engineered cell therapy for solid tumour treatment. The therapy, which targets the MAGE-A4 antigen, achieved a 43% overall response rate in a phase 2 trial involving 44 patients with advanced synovial sarcoma. The firm will produce the therapy at its Philadelphia site with sales expected in Q4 2021. Tecelra is listed at $727,000.